Live Deal Pipeline
Deal detail
Browse Samjong KPMG's control sale, investment, and real-estate opportunities in one place.
Healthcare & BiotechPublished deal
Project Cellis - Financing
Investment opportunity in a company operating Korea's leading cell-and-gene-therapy platform specializing in regenerative medicine
| Location | Korea |
|---|---|
| Industry | Healthcare & Biotech |
| Revenue | Contact us |
| Asking | KRW [xx] hundred million on a 100% equity basis (negotiable) |
| Deal structure | Capital injection; investment structure negotiable |
| Financials | Contact us |
Investment highlights
- Integrated biotechnology cluster encompassing cell banking, GMP manufacturing, healthcare, and bio-insurance services
- Operates an autologous-cell regenerative-medicine business by adapting Japan's bio-insurance model for Korea
- K-Cell-based cell-therapy R&D capabilities and technologies; selected as a government-designated K-Cell specialized research institute
- Ranks among the global top ten companies for stem-cell technology patents
- Operates six leading cell- and gene-therapy manufacturing facilities across Korea, the United States, and Japan
Deal partner
Yunseong Han, Partner